Literature DB >> 16221702

Diagnostic potential of circulating natriuretic peptides in chronic kidney disease.

Patrick B Mark1, Graham A Stewart, Ron T Gansevoort, Colin J Petrie, Theresa A McDonagh, Henry J Dargie, R Stuart C Rodger, Alan G Jardine.   

Abstract

BACKGROUND: Measurement of natriuretic peptides, particularly brain natriuretic peptide (BNP) is an established method for the diagnosis of cardiovascular disorders, chiefly left ventricular (LV) dysfunction. The influence of renal function on the diagnostic utility of natriuretic peptides is unclear.
METHODS: We performed a cross-sectional study of 296 patients with renal disease but no history of cardiac disease using echocardiography to assess LV mass and function. Circulating levels of atrial natriuretic peptide (ANP) and BNP were also measured.
RESULTS: The incidence of LV hypertrophy increased with progressive renal dysfunction; from 39% in patients with near-normal renal function, to 80% in renal transplant patients. There was a negative correlation between both ANP and BNP, and glomerular filtration rate (GFR) (ANP: r = -0.28, P<0.001; BNP: r = -0.40, P<0.001). Serum ANP and BNP had sensitivity and specificity for LV hypertrophy of 39.9%, 87.4% (ANP) and 61.4%, 67.6% (BNP) respectively. Sensitivity and specificity for LV dysfunction was 77.2%, 32.4% (ANP) and 71.8%, 40.0% (BNP). Significant confounders in determining serum ANP were haemoglobin, beta blockade and albumin, while serum BNP levels were significantly confounded by GFR, albumin, haemoglobin, beta blockade and age.
CONCLUSIONS: Across a spectrum of renal dysfunction, GFR is a more important determinant of serum BNP than ventricular function, and several factors are predictors of natriuretic peptide levels. In chronic kidney disease, the use of natriuretic peptides to diagnose LV hypertrophy must be interpreted in light of these other factors. The use of these peptides in renal dysfunction to diagnose LV dysfunction may be of limited value.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221702     DOI: 10.1093/ndt/gfi187

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  Are levels of NT-proBNP and SDMA useful to determine diastolic dysfunction in chronic kidney disease and renal transplant patients?

Authors:  Lidija Memon; Vesna Spasojevic-Kalimanovska; Natasa Bogavac Stanojevic; Jelena Kotur-Stevuljevic; Sanja Simic-Ogrizovic; Vojislav Giga; Violeta Dopsaj; Zorana Jelic-Ivanovic; Slavica Spasic
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

2.  B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis.

Authors:  Matthew A Roberts; Piyush M Srivastava; Neil Macmillan; David L Hare; Sujiva Ratnaike; Ken Sikaris; Francesco L Ierino
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

Review 3.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

4.  Association of B-type natriuretic Peptide levels with estimated glomerular filtration rate and congestive heart failure.

Authors:  Carmen L Wiley; Sean P Switzer; Richard L Berg; Ingrid Glurich; Richard A Dart
Journal:  Clin Med Res       Date:  2009-11-17

5.  Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease.

Authors:  B Tirmenstajn-Jankovic; N Dimkovic; G Perunicic-Pekovic; Z Radojicic; D Bastac; S Zikic; M Zivanovic
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

6.  Hypertrophic gene expression induced by chronic stretch of excised mouse heart muscle.

Authors:  Anna M Raskin; Masahiko Hoshijima; Eric Swanson; Andrew D McCulloch; Jeffrey H Omens
Journal:  Mol Cell Biomech       Date:  2009-09

7.  Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial.

Authors:  Ramon Paniagua; Dante Amato; Salim Mujais; Edward Vonesh; Alfonso Ramos; Ricardo Correa-Rotter; Walter H Horl
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 8.237

Review 8.  Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.

Authors:  Jun R Chiong; Geoffrey T Jao; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 9.  Selected cardiovascular risk factors in early stages of chronic kidney disease.

Authors:  Joanna Jagieła; Piotr Bartnicki; Jacek Rysz
Journal:  Int Urol Nephrol       Date:  2020-01-18       Impact factor: 2.370

10.  Relationship between serum brain natriuretic peptide and heart function in patients with chronic kidney disease.

Authors:  Jae Won Yang; Min Soo Kim; Jae Seok Kim; Jong Myoung Yoo; Seung Tae Han; Bi Ro Kim; Yun Deok Kim; Jeong Wook Choi; Seung Ok Choi; Byoung Geun Han
Journal:  Korean J Intern Med       Date:  2008-12       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.